Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MindShift Compounds
Cham, Zug, Switzerlandthinktankphoto.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MindShift Compounds AG has synthesized initial next-gen psychedelic compounds. These are being advanced into first-in-human Phase 1 trials through a partnership with MindMed. The company’s work expands the pipeline for novel psychiatric therapeutics targeting mental health conditions such as addiction and depression. Patent applications have been filed for these new substances.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
MindMedUniversity Hospital Basel’s Liechti Lab
Beyond the preview
Go deeper on MindShift Compounds.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MindShift Compounds.